Consensus Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
40.9 ^CNY	+0.64%		-2.90%	-14.52%

May. 24	Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	CI
Apr. 29	Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

74a18a273a.aWO4RlYs3lecaQ-HQhlUji0t953gkcGwetocx2u2A6w.Hg72CSB-igf7PUDUACgG4Hd8mc6F1o6dCIhK8xrpe8BeK9AnEVroOO4zSg~00b3944d7c3d71faf5c88babf68d4f73

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.9 CNY

Average target price

54 CNY

Spread / Average Target

+32.03%

High Price Target

54 CNY

Spread / Highest target

+32.03%

Low Price Target

54 CNY

Spread / Lowest Target

+32.03%

Trading Rating

Investor Rating

ESG Refinitiv